Edaglitazone

Edaglitazone is a potent, selective and orally active PPARγ agonist, with EC50s of 35.6 nM and 1053 nM for PPARα and PPARγ, respectively. Edaglitazone displays antiplatelet, antidiabetic and anti-hyperglycemic activity[1][2][3].

Product Specifications

CAS Number

213411-83-7

UNSPSC

12352005

Target

PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/edaglitazone.html

Purity

99.58

Solubility

DMSO : 30 mg/mL (ultrasonic)

Smiles

CC1=C(N=C(C2=CC=CC=C2)O1)CCOC3=CC=C(C4=C3C=CS4)CC(S5)C(NC5=O)=O

Molecular Formula

C24H20N2O4S2

Molecular Weight

464.56

References & Citations

[1]Dietz M, et, al. Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. ChemMedChem. 2012 Jun;7 (6) :1101-11. |[2]Fürnsinn C, et, al. Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism. Br J Pharmacol. 1999 Nov;128 (6) :1141-8.|[3]Muñoz-Gutiérrez C, et, al. Study of the interactions between Edaglitazone and Ciglitazone with PPARγ and their antiplatelet profile. Life Sci. 2017 Oct 1;186:59-65.